This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
SAM-e
SAM-e is the universal methyl donor — a single biochemical currency that the body spends on neurotransmitter synthesis (serotonin, dopamine, norepinephrine, melatonin), DNA methylation, phosphatidy…
Aliases (5)
Overview
What is SAM-e?
SAM-e is the universal methyl donor — a single biochemical currency that the body spends on neurotransmitter synthesis (serotonin, dopamine, norepinephrine, melatonin), DNA methylation, phosphatidylcholine production, joint proteoglycan synthesis, and Phase II liver detox. As a supplement, it has three real-world use cases backed by clinical trials: (1) mild-to-moderate depression — efficacy comparable to imipramine and escitalopram in pooled 2024 meta-analyses (PMIDs 38423354, 38199136), with faster onset and better tolerability than SSRIs; (2) osteoarthritis — pain reduction comparable to celecoxib and NSAIDs without GI ulceration risk (PMIDs 12019049, 15102339); (3) intrahepatic cholestasis / alcoholic liver disease — modest but reproducible hepatoprotection (PMID 22659519). For a 20-year-old MMA athlete with no depressive episodes, no joint disease, and untested methylation status, SAM-e is OPTIONAL-ADD, LOW-PRIORITY — keep it on the shelf as a situational tool for post-fight emotional letdown, a future MTHFR C677T finding with elevated homocysteine on bloodwork, or oral-steroid liver protection (paired with TUDCA). Hard blocks: bipolar (mania risk), current SSRI/SNRI/MAOI/tramadol user (serotonin syndrome risk). Enteric coating is non-negotiable — non-coated SAM-e degrades in stomach acid (<1% bioavailability).
Peptide Interactions
Essential co-supplements. Prevent paradoxical homocysteine elevation. The MTHF + methyl-B12 + SAM-e triad is the foundational methylation stack.
Required for transsulfuration arm — clears homocysteine via cystathionine β-synthase. Especially relevant in CBS variants.
Alternative methyl donor and homocysteine remethylation pathway (BHMT). Synergistic for methylation support; particularly useful in MTHFR carriers.
Synergistic for liver protection — different mechanism (bile-acid signaling vs methyl donation). Standard stack for oral anabolic steroid users.
Independent antidepressant effects + methylation-supportive (DHA is a substrate for SAM-e-dependent methylation in neuronal membranes). Adjunctive in depress…
Cofactor for ATP regeneration → methionine adenosyltransferase activity. Generic supportive role.
Counters the activation/anxiety subset effect for users who get jittery on SAM-e. Anecdotal but well-tolerated.
Serotonin syndrome risk. Medical supervision required.
SAM-e can methylate L-dopa via COMT, reducing efficacy. Parkinson's patients on L-dopa need physician oversight.
Niacin is a methyl-group sink (NNMT converts nicotinamide to N-methylnicotinamide using SAM-e). High-dose niacin can deplete SAM-e — counterproductive.
Methylation pathway interactions; possible serotonin syndrome risk.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
Common (5-15%):
- GI upset — nausea, mild stomach discomfort (usually transient, week 1-2)
- Insomnia / activation if dosed PM (move to AM)
- Headache (mild, dose-dependent)
- Mild anxiety / restlessness (catecholaminergic activation)
- Dry mouth, increased sweating
Less common (1-5%):
- Palpitations / tachycardia (catecholaminergic; usually mild and dose-related)
- Hypomanic symptoms — irritability, racing thoughts, decreased sleep need (warning sign; reduce dose or stop)
- Diarrhea
- Vivid dreams (likely melatonin-pathway methylation effects)
Rare-serious (<1% but clinically important):
- Manic switch in bipolar individuals — HARD BLOCK. Same risk pattern as SSRIs (10-30% in untreated bipolar I); possibly faster onset given direct catecholamine substrate provision. SAM-e can precipitate mania in bipolar individuals who were not yet diagnosed — first manic episode under SAM-e is documented in case reports. Bipolar I and bipolar II are both at risk; cyclothymia probably similar.
- Serotonin syndrome with serotonergic drugs. Theoretical and case-documented in combination with SSRIs/SNRIs/MAOIs/tramadol/triptans/St. John's Wort. Mechanism: increased methyl supply may indirectly boost serotonin synthesis, plus direct effects on monoamine availability. Hard interaction; medical supervision required if combining.
- Paradoxical homocysteine elevation. SAM-e supplementation increases SAH (S-adenosyl-homocysteine) which is hydrolyzed to homocysteine. Without adequate B12, folate, B6 cofactors to recycle homocysteine, plasma homocysteine can paradoxically rise. Always pair SAM-e with methyl-B12 + methyl-folate (or 5-MTHF) and B6/P5P, especially in MTHFR carriers.
- Anxiety amplification in pre-existing anxiety disorders. Some users with GAD or panic disorder report worsening; mechanism is catecholaminergic activation.
- Allergic skin reactions (rare, idiosyncratic).
Specific watch periods:
- Days 1-7: Activation symptoms (anxiety, insomnia, GI). Reduce dose if intolerable; titrate slower.
- Weeks 2-6: Mood-response window. Hypomania warning signs require dose hold and re-evaluation.
- Months 3-6: Methyl-cycle cofactor depletion can present as fatigue, low mood — paradoxical "burnout." Check B12, folate, homocysteine.
References
Limveeraprajak et al. 2024 — SAMe for depression meta-analysis (23 RCTs, 2,183 participants)
PMID 38423354
View StudyPeng et al. 2024 — SAMe adjuvant for depression meta-analysis (14 RCTs, 1,522 participants)
PMID 38199136
View StudyGalizia et al. 2016 — Cochrane SAMe for depression review
PMID 27727432
View StudySarris et al. 2014 — SAMe vs escitalopram vs placebo Australian RCT
PMID 24856557
View StudySarris et al. 2015 — Sex-modified SAMe response in depression
PMID 26011569
View StudySoeken et al. 2002 — SAMe for osteoarthritis meta-analysis (J Fam Pract)
PMID 12019049
View StudyNajm et al. 2004 — SAMe vs celecoxib for knee OA (BMC Musculoskelet Disord)
PMID 15102339
View StudyAnstee + Day 2012 — SAMe therapy in liver disease (J Hepatol)
PMID 22659519
View StudyBarbier-Torres, Mato, Lu 2025 — MAT1A and SAMe in alcohol-associated liver disease (Antioxidants)
PMID 41462685
View Study2024 MTHFR structural biology — SAM-allosteric inhibition
PMID 38886362
View Study2024 one-carbon cycle biomarkers + depressive tendencies
PMID 39315125
View StudyWikipedia: S-Adenosyl methionine
chemistry, history, regulatory status by country
View Studyr/NooTopics oral bioavailability table
non-enteric SAM-e <1% bioavailability reference
View StudyConsumerLab SAMe product review
independent quality testing of US SAMe brands (subscription)
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.